Skip to main navigation
  • Careers
  • Partnerships & Business Development
  • Contact Us
Link to  Esperion Therapeutics, Inc. Homepage
  • Company
    • About Us
    • Leadership Team
    • Board of Directors
    • Ethics and Compliance
    • Corporate Governance & Committee Composition
  • Products
  • Science
    • Unmet Need
    • Scientific Resources
    • Scientific Advisory Board
    • Pipeline
    • Grants
  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs

Newsroom

Esperion to Report Second Quarter 2022 Financial Results August 2, 2022
Jul 12, 2022
PDF Version
Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin
Jun 03, 2022
PDF Version
Esperion to Participate in the 2022 Jefferies Global Healthcare Conference
Jun 02, 2022
PDF Version
Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors
Jun 01, 2022
PDF Version
Esperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions
May 31, 2022
PDF Version
  • First page «
  • Previous page ‹
  • …
  • Page 32
  • Page 33
  • Current page 34
  • Page 35
  • Page 36
  • …
  • Next page ›
  • Last page »

Media Information

To speak with a member of our PR team, or to schedule an interview, please contact Esperion Corporate Communications by phone at +1 734-887-3903, or by email at corporateteam@esperion.com.


 
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

 
Corporate Inquiries & Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

 

Email Alerts

  • OUR COMPANY
  • About Us
  • Leadership Team
  • Board of Directors
  • Ethics and Compliance
  • Corporate Governance & Committee Composition
  • PRODUCTS
  • SCIENCE
  • Unmet Need
  • Scientific Resources
  • Scientific Advisory Board
  • Pipeline
  • Grants
  • CAREERS
  • Partnerships & Business Development
  • INVESTORS & MEDIA
  • Overview
  • Newsroom
  • Events
  • Financial Information
  • Stock Information & Analyst Coverage
  • FAQs
  • Contact Us
Great place to work certified | JUN 2024 - JUN 2025 | USA

All trademarks and trade names are the property of their respective owners.

© 2026 Esperion Therapeutics, Inc. All rights reserved.

  • Privacy Policy
  • Terms of Use
  • Accessibility Statement
  • Social Media Community Guidelines
  • facebook
  • instagram
  • linkedin
  • twitter
  • rss
Search Investors